Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma

Oh, DH; Ma, X; Hogg, SJ; He, J; Kearney, C; Brasacchio, D; Susanto, O; Maher, B; Jennings, IG; Newbold, A; Fraser, P; Gruber, E; Kats, LM; Gregory, GP; Johnstone, RW; Thompson, PE; Shortt, J

Author(s): Oh, DH; Ma, X; Hogg, SJ; He, J; Kearney, C; Brasacchio, D; Susanto, O; Maher, B; Jennings, IG; Newbold, A; Fraser, P; Gruber, E; Kats, LM; Gregory, GP; Johnstone, RW; Thompson, PE; Shortt, J;
Details: Publication Year 2023-09-05,Volume 120,Issue #36,Page e2306414120
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Publication Type: Research article
Abstract: Targeted inhibitors of bromodomain and extraterminal (BET)-bromodomains and phosphatidylinositol-3-kinase (PI3K) signaling demonstrate potent but self-limited antilymphoma activity as single agents in the context of cellular Myelocytomatosis (cMYC) oncogene-dysregulation. However, combined PI3K and BET inhibition imparts synergistic anticancer activity with the potential for more sustained disease responses due to the mutual antagonism of compensatory epigenetic and signaling networks. Here, we describe the mechanistic and therapeutic validation of rationally designed dual PI3K/BET bromodomain inhibitors, built by linkage of established PI3K and BET inhibitor pharmacophores. The lead candidate demonstrates high selectivity, nanomolar range cellular potency, and compelling in vivo efficacy, including curative responses in the aggressive Emicro-Myc lymphoma model. These studies further support the therapeutic strategy of combined PI3K and BET inhibition and provide a potential step-change in approach to orthogonal MYC antagonism using optimized chimeric small-molecule technology.
Publisher: National Academy of Sciences
Keywords: Humans; *Phosphatidylinositol 3-Kinases; Phosphatidylinositol 3-Kinase; Aggression; Epigenomics; *Lymphoma/drug therapy; Phosphoinositide-3 Kinase Inhibitors; BET-bromodomains; cMYC; chimeric small molecules; phosphatidylinositol-3-kinase
Department(s): Laboratory Research
PubMed ID: 37643213
Publisher's Version: https://doi.org/10.1073/pnas.2306414120
Open Access at Publisher's Site: https://doi.org/10.1073/pnas.2306414120
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-11-08 07:27:53

Last Modified: 2023-11-08 07:28:27